Stifel Raises Syndax Pharmaceuticals Stock Price... - May 4

The Story

Stifel raised its price target on Syndax Pharmaceuticals, citing a stronger therapy outlook, and the news pushed $SNDX higher. The stock climbed 9.71% to $22.91, compared with a nearby reference of $22.71, as markets reacted to the analyst action.

Why It Matters For Your Portfolio

• New price target: Stifel moved its target to $45.00 from $44.00, setting an analyst benchmark well above recent trading levels and highlighting perceived upside versus $22.91.
• Immediate market response: The 9.71% jump shows the stock is sensitive to analyst views, which can amplify short-term volatility for $SNDX.
• Volatility signals: Intraday bands and related moves of 4.98%, 0.20% and 1% point to fluctuating trader activity, which could affect entry and exit timing.

The Trade

Growth investors and event-driven traders should pay attention, as analyst upgrades and therapy catalysts tend to move small-cap biotech names. Watch upcoming therapy milestones and further analyst commentary, and use $22.71 as a near-term reference and the $45.00 target as the analyst-implied level. This note is informational only and not personalized investment advice.